hCD3EDG/hBCMA(BALB/c)

Nomenclature

BALB/cJSmo-Bcmatm1(hTNFRSF17)Cd3etm1(hCD3E)Cd3dtm1(hCD3D)Cd3gtm1(hCD3G)Smoc

Cat. NO.

NM-XA-250066

Strain State

Repository Live

Export PDF

Model Description

The hBCMA(BALB/c) (NM-HU-241173) was crossed with hCD3EDG(BALB/c)(NM-HU-220122) to generate hBCMA(BALB/c)/hCD3EDG(BALB/c) mice.

Validation Data

bf9d4f66-f400-45f0-8558-dcc54e5bd19a.png

Fig.1 Detection of hBCMA expression on TACI+CD138+ cells in spleen and bone marrow of WT BALB/c mice and HO hCD3EDG/hBCMA(BALB/c) mice by FACS. Leukocytes were collected from wild-type BALB/c mice (female, 8 weeks old) and homozygous hCD3EDG/hBCMA(BALB/c) humanized mice (female, 7 weeks old), and analyzed by flow cytometry with anti-hBCMA. 

Abbr. HO, homozygous; WT, wild type.

74f2ba78-781a-4fc3-b0da-680c5b4e0e36.png

Fig 2. Frequency of leukocyte and myeloid subpopulations in the spleen by flow cytometry

Spleen was collected from WT BALB/C mice and HO/HO hCD3EDG/hBCMA(BALB/C) mice (7-week-old, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the spleen. Bar indicated expressed as mean ± SEM.

Abbr.  HO/HO, homozygous; WT, wild type.

bc2f49e8-6da2-4dac-8ba3-d82953cc988a.png

Fig 3. Frequency of leukocyte and myeloid subpopulations in the BM by flow cytometry

BM was collected from WT BALB/C mice and HO/HO hCD3EDG/hBCMA(BALB/C) mice (7-week-old, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the BM. Bar indicated expressed as mean ± SEM.

Abbr.  HO/HO, homozygous; WT, wild type.

a364b3f1-2b42-49d2-8f55-f31b52c3912f.png

Fig 4. Frequency of leukocyte and myeloid subpopulations in the blood by flow cytometry

Blood was collected from WT BALB/C mice and HO/HO hCD3EDG/hBCMA(BALB/C) mice (7-week-old, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the blood. Bar indicated expressed as mean ± SEM.

Abbr.  HO/HO, homozygous; WT, wild type.

image.png

Table 1. Blood routine examination of hCD3EDG/ hBCMA(BALB/c) knockin mice. Values are expressed as mean±SEM.

Abbr. HO, homozygous; WT, wild type.

image.png

Fig 5. In vivo efficacy study of teclistamab in HO hCD3EDG/hBCMA(BALB/c) mice. 

Teclistamab were injected at day 0, 3, 5,  and immune cells in the spleen and bone marrow of mice after therapy were measured by flow cytometry (n=4). Values are shown as mean ± SEM.


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more

Milestones

Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.

Learn more